BRAF and NRAS Mutations in Papillary Thyroid Carcinoma and Concordance in BRAF Mutations Between Primary and Corresponding Lymph Node Metastases
Abstract Concordance between mutations in the primary papillary thyroid carcinoma (PTC) and the paired x lymph node metastasis may elucidate the potential role of molecular targeted therapy in advanced stages. BRAF and NRAS mutations in primary PTC (n = 253) with corresponding metastatic lymph node...
Guardado en:
| Autores principales: | , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Nature Portfolio
2017
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/8a8ea26afe584a07ba14c899f9cf44d8 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:8a8ea26afe584a07ba14c899f9cf44d8 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:8a8ea26afe584a07ba14c899f9cf44d82021-12-02T11:51:11ZBRAF and NRAS Mutations in Papillary Thyroid Carcinoma and Concordance in BRAF Mutations Between Primary and Corresponding Lymph Node Metastases10.1038/s41598-017-04948-32045-2322https://doaj.org/article/8a8ea26afe584a07ba14c899f9cf44d82017-07-01T00:00:00Zhttps://doi.org/10.1038/s41598-017-04948-3https://doaj.org/toc/2045-2322Abstract Concordance between mutations in the primary papillary thyroid carcinoma (PTC) and the paired x lymph node metastasis may elucidate the potential role of molecular targeted therapy in advanced stages. BRAF and NRAS mutations in primary PTC (n = 253) with corresponding metastatic lymph node (n = 46) were analyzed utilizing StripAssays (ViennaLab Diagnostics). Statistical analysis was performed using (SPSS, Inc.), version 24.0 with a p-value of <0.05, and concordance via kappa agreement. BRAF mutation frequency in conventional PTC (cPTC): 56.8%, papillary thyroid microcarcinoma (PTMC): 36.5%, PTMC-FV: 2.7% and PTC-FV: 4.1%. NRAS mutation frequency in PTC-FV: 28.6%, PTMC: 28.6%, PTMC-FV: 23.8%, and cPTC: 19.0%. BRAF mutation correlation with older age in cPTC (42.6 versus 33.6) years (p < 0.001) was the only significant clinicopathologic parameter. BRAF mutations were concordant in the primary and its corresponding lymph node deposits in PTC with a kappa of 0.77 (p-value < 0.0001). BRAF mutations are predominant in cPTC and PTMC while NRAS mutations in PTC-FV. BRAF mutation is conserved in metastatic lymph node deposits, thus BRAF is an early mutational pathogenetic driver. Therefore, targeted therapy is potential in recurrent and advanced stage disease.Najla FakhruddinMark JabbourMichael NovyHani TamimHisham BahmadFadi FarhatGhazi ZaatariTarek AridiGernot KriegshauserChristian OberkaninsRami MahfouzNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 7, Iss 1, Pp 1-11 (2017) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R Science Q |
| spellingShingle |
Medicine R Science Q Najla Fakhruddin Mark Jabbour Michael Novy Hani Tamim Hisham Bahmad Fadi Farhat Ghazi Zaatari Tarek Aridi Gernot Kriegshauser Christian Oberkanins Rami Mahfouz BRAF and NRAS Mutations in Papillary Thyroid Carcinoma and Concordance in BRAF Mutations Between Primary and Corresponding Lymph Node Metastases |
| description |
Abstract Concordance between mutations in the primary papillary thyroid carcinoma (PTC) and the paired x lymph node metastasis may elucidate the potential role of molecular targeted therapy in advanced stages. BRAF and NRAS mutations in primary PTC (n = 253) with corresponding metastatic lymph node (n = 46) were analyzed utilizing StripAssays (ViennaLab Diagnostics). Statistical analysis was performed using (SPSS, Inc.), version 24.0 with a p-value of <0.05, and concordance via kappa agreement. BRAF mutation frequency in conventional PTC (cPTC): 56.8%, papillary thyroid microcarcinoma (PTMC): 36.5%, PTMC-FV: 2.7% and PTC-FV: 4.1%. NRAS mutation frequency in PTC-FV: 28.6%, PTMC: 28.6%, PTMC-FV: 23.8%, and cPTC: 19.0%. BRAF mutation correlation with older age in cPTC (42.6 versus 33.6) years (p < 0.001) was the only significant clinicopathologic parameter. BRAF mutations were concordant in the primary and its corresponding lymph node deposits in PTC with a kappa of 0.77 (p-value < 0.0001). BRAF mutations are predominant in cPTC and PTMC while NRAS mutations in PTC-FV. BRAF mutation is conserved in metastatic lymph node deposits, thus BRAF is an early mutational pathogenetic driver. Therefore, targeted therapy is potential in recurrent and advanced stage disease. |
| format |
article |
| author |
Najla Fakhruddin Mark Jabbour Michael Novy Hani Tamim Hisham Bahmad Fadi Farhat Ghazi Zaatari Tarek Aridi Gernot Kriegshauser Christian Oberkanins Rami Mahfouz |
| author_facet |
Najla Fakhruddin Mark Jabbour Michael Novy Hani Tamim Hisham Bahmad Fadi Farhat Ghazi Zaatari Tarek Aridi Gernot Kriegshauser Christian Oberkanins Rami Mahfouz |
| author_sort |
Najla Fakhruddin |
| title |
BRAF and NRAS Mutations in Papillary Thyroid Carcinoma and Concordance in BRAF Mutations Between Primary and Corresponding Lymph Node Metastases |
| title_short |
BRAF and NRAS Mutations in Papillary Thyroid Carcinoma and Concordance in BRAF Mutations Between Primary and Corresponding Lymph Node Metastases |
| title_full |
BRAF and NRAS Mutations in Papillary Thyroid Carcinoma and Concordance in BRAF Mutations Between Primary and Corresponding Lymph Node Metastases |
| title_fullStr |
BRAF and NRAS Mutations in Papillary Thyroid Carcinoma and Concordance in BRAF Mutations Between Primary and Corresponding Lymph Node Metastases |
| title_full_unstemmed |
BRAF and NRAS Mutations in Papillary Thyroid Carcinoma and Concordance in BRAF Mutations Between Primary and Corresponding Lymph Node Metastases |
| title_sort |
braf and nras mutations in papillary thyroid carcinoma and concordance in braf mutations between primary and corresponding lymph node metastases |
| publisher |
Nature Portfolio |
| publishDate |
2017 |
| url |
https://doaj.org/article/8a8ea26afe584a07ba14c899f9cf44d8 |
| work_keys_str_mv |
AT najlafakhruddin brafandnrasmutationsinpapillarythyroidcarcinomaandconcordanceinbrafmutationsbetweenprimaryandcorrespondinglymphnodemetastases AT markjabbour brafandnrasmutationsinpapillarythyroidcarcinomaandconcordanceinbrafmutationsbetweenprimaryandcorrespondinglymphnodemetastases AT michaelnovy brafandnrasmutationsinpapillarythyroidcarcinomaandconcordanceinbrafmutationsbetweenprimaryandcorrespondinglymphnodemetastases AT hanitamim brafandnrasmutationsinpapillarythyroidcarcinomaandconcordanceinbrafmutationsbetweenprimaryandcorrespondinglymphnodemetastases AT hishambahmad brafandnrasmutationsinpapillarythyroidcarcinomaandconcordanceinbrafmutationsbetweenprimaryandcorrespondinglymphnodemetastases AT fadifarhat brafandnrasmutationsinpapillarythyroidcarcinomaandconcordanceinbrafmutationsbetweenprimaryandcorrespondinglymphnodemetastases AT ghazizaatari brafandnrasmutationsinpapillarythyroidcarcinomaandconcordanceinbrafmutationsbetweenprimaryandcorrespondinglymphnodemetastases AT tarekaridi brafandnrasmutationsinpapillarythyroidcarcinomaandconcordanceinbrafmutationsbetweenprimaryandcorrespondinglymphnodemetastases AT gernotkriegshauser brafandnrasmutationsinpapillarythyroidcarcinomaandconcordanceinbrafmutationsbetweenprimaryandcorrespondinglymphnodemetastases AT christianoberkanins brafandnrasmutationsinpapillarythyroidcarcinomaandconcordanceinbrafmutationsbetweenprimaryandcorrespondinglymphnodemetastases AT ramimahfouz brafandnrasmutationsinpapillarythyroidcarcinomaandconcordanceinbrafmutationsbetweenprimaryandcorrespondinglymphnodemetastases |
| _version_ |
1718395175324090368 |